---
title: "Viatris Inc. (VTRS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VTRS.US.md"
symbol: "VTRS.US"
name: "Viatris Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:24:28.825Z"
locales:
  - [en](https://longbridge.com/en/quote/VTRS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VTRS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VTRS.US.md)
---

# Viatris Inc. (VTRS.US)

## Company Overview

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.viatris.com](https://www.viatris.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.62)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 125 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.62% |  |
| Net Profit YoY | 92.18% |  |
| P/B Ratio | 1.28 |  |
| Dividend Ratio | 2.97% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 18830816415.18 |  |
| Revenue | 14562600000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -1.96% | D |
| Profit Margin | -2.04% | D |
| Gross Margin | 39.18% | B |
| Revenue YoY | 1.62% | C |
| Net Profit YoY | 92.18% | A |
| Total Assets YoY | -4.26% | D |
| Net Assets YoY | -6.34% | D |
| Cash Flow Margin | -731.43% | E |
| OCF YoY | 1.62% | C |
| Turnover | 0.39 | C |
| Gearing Ratio | 60.21% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Viatris Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.62%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "92.18%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.97%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "18830816415.18",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "14562600000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-1.96%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-2.04%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "39.18%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "1.62%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "92.18%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-4.26%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-6.34%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-731.43%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "1.62%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.39",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "60.21%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -63.51 | 223/189 | - | - | - |
| PB | 1.28 | 65/189 | 1.09 | 0.81 | 0.70 |
| PS (TTM) | 1.29 | 37/189 | 1.12 | 0.88 | 0.76 |
| Dividend Yield | 2.97% | 12/189 | 5.15% | 4.49% | 3.47% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 45% |
| Overweight | 1 | 9% |
| Hold | 4 | 36% |
| Underweight | 1 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.17 |
| Highest Target | 20.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/VTRS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/VTRS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/VTRS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/VTRS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**